Transfusion Therapy Videos
TDT expert Dr. Cappellini discusses transfusion therapy, iron monitoring, chelation, adherence to treatment and her key takeaways.
Chapter 1: Transfusion Therapy
Dr. Cappellini talks about the role of chronic red blood cell transfusion in the management of TDT, treatment goals, and how it leads to iron overload.
Chapter 2: Iron Monitoring and Chelation
Dr. Cappellini discusses the role of iron monitoring and the goals of iron chelation in the treatment of iron overload caused by chronic transfusion therapy in TDT.
Hematopoietic Stem Cell Transplantation Videos
HSCT expert Dr. Baronciani discusses the history of HSCT, clinical outcomes in patients with TDT and making the decision to undergo HSCT.
Chapter 1: History of HSCT for Beta-Thalassemia
Dr. Baronciani talks about the history of HSCT in TDT and her team’s first analysis of outcomes in TDT patients from the European Society for Blood and Marrow Transplantation (EBMT) registry.
Chapter 2: Clinical Outcomes of HSCT in Patients With TDT
Dr. Baronciani discusses her team’s latest analysis of HSCT clinical outcomes in TDT patients who underwent the procedure between 2000 and 2017.
Transfusion-Dependent Beta-Thalassemia (TDT) Is A Severe Genetic Disease That Impacts Patients for Life
This PDF summarizes the main characteristics of TDT, the complications and limitations of red blood cell transfusions, and available TDT treatment options.
Allogeneic HSCT Is a Treatment Option with the Potential to Correct the Genetic Deficiency of Beta-Thalassemia
This PDF summarizes the benefits and risks of allogeneic HSCT and the kinds of TDT patients it might be suitable for.
Help patients better understand the current impact TDT has on their lives, set goals, and plan for the future.
bluebird bio, Inc. is not responsible for the content provided by third party sites, nor does bluebird bio, Inc. endorse the content of these sites. Above is not a comprehensive list of resources and it is provided for reference only.
bluebird bio, Inc. is not responsible for the content provided by third party sites, nor does bluebird bio, Inc. endorse the content of these sites. Below is not a comprehensive list of resources and it is provided for reference only.
Beta-Thalassemia and TDT
Find information about long-term survival rates of TDT patients treated with hematopoietic stem cell transplantation and analysis stressing the importance of long-term follow-up after hematopoietic stem cell transplantation.
Long-term survival of Beta-thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.
Find guidelines for the standard monitoring of patients with thalassemia, how chronic transfusion therapy extends life expectancy, and complications of therapy.
Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort.
Learn more about hematopoietic stem cell transplantation in thalassemia, effects on patient quality of life, managing iron overload and sickle cell anemia.
Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000‑2010.
Quality of Life in Thalassemia: A Comparison of SF-36 Results from the Thalassemia Longitudinal Cohort to Reported Literature and the US Norms.
Register now to receive resources to help support your TDT patients, invites to future webinars, and additional information about beta‑thalassemia.Register for Resources